Home » ELI LILLY STARTS TRIAL OF ENZASTAURIN
ELI LILLY STARTS TRIAL OF ENZASTAURIN
Eli Lilly will treat nearly 400
patients with glioblastoma multiforme with either enzastaurin or the common chemotherapeutic
agent CeeNU in a Phase III trial that the company has dubbed STEERING (for Study
Evaluating Enzastaurin in Recurrent Glioblastoma).
Enzastaurin, which
has been granted orphan-drug status by the FDA, is an oral serine-threonine kinase
inhibitor. The company is studying whether enzastaurin could be useful in treating
other cancers, including non-Hodgkin's lymphoma, colorectal cancer and non-small
cell lung cancer.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May